Physician profile
Cheng Chu
NPI 1578824058
$8,485.87
in general payments reported to CMS, 2019-2025
28 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $399 · 2021: $1,930 · 2022: $1,260 · 2023: $1,498 · 2024: $1,274 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,989 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,988.94 |
| Education | $191.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,124.21 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $867.45 | 2019-2025 | Lokelma, Farxiga, Evusheld |
| Baxter Healthcare | $862.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $549.62 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $500.11 | 2019-2024 | Veltassa |
| Travere Therapeutics, INC. | $430.81 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $369.43 | 2020-2025 | Acthar, Terlivaz |
| Glaxosmithkline, LLC. | $333.11 | 2021-2025 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $304.62 | 2020-2025 | Rayaldee |
| Akebia Therapeutics INC | $304.58 | 2020-2024 | Auryxia, Vafseo |
| Recor Medical INC | $302.44 | 2025 | Paradise Ultrasound Renal Denervation System |
| Amgen INC. | $298.63 | 2020-2024 | Tavneos, Parsabiv, Aranesp |
| Horizon Therapeutics Plc | $281.72 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $275.25 | 2021-2025 | |
| Daiichi Sankyo INC. | $223.43 | 2019-2024 | Injectafer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $218.51 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $215.58 | 2019-2025 | Ultomiris, Soliris |
| Veloxis Pharmaceuticals, INC. | $206.31 | 2019-2025 | Envarsus |
| Mallinckrodt Enterprises LLC | $180.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $156.14 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.40 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $102.33 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $98.47 | 2022-2025 | Purified Cortrophin Gel |
| Shire North American Group INC | $45.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.50 | 2021-2022 | |
| Novo Nordisk INC | $32.96 | 2023-2025 | Ozempic, Rybelsus |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.28 | 2025 | |
| Bard Peripheral Vascular, INC. | $14.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheng Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.